NZ510121A - Use of VEGF-C or VEGF-D gene or protein to prevent restenosis of blood vessels - Google Patents

Use of VEGF-C or VEGF-D gene or protein to prevent restenosis of blood vessels

Info

Publication number
NZ510121A
NZ510121A NZ510121A NZ51012199A NZ510121A NZ 510121 A NZ510121 A NZ 510121A NZ 510121 A NZ510121 A NZ 510121A NZ 51012199 A NZ51012199 A NZ 51012199A NZ 510121 A NZ510121 A NZ 510121A
Authority
NZ
New Zealand
Prior art keywords
vegf
gene
protein
blood vessels
polypeptide
Prior art date
Application number
NZ510121A
Other languages
English (en)
Inventor
Mikko O Hiltunen
Markku M Jeltsch
Marc G Achen
Seppo Yla-Herttuala
Kari Alitalo
Original Assignee
Licentia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Licentia Ltd filed Critical Licentia Ltd
Publication of NZ510121A publication Critical patent/NZ510121A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NZ510121A 1998-10-26 1999-10-26 Use of VEGF-C or VEGF-D gene or protein to prevent restenosis of blood vessels NZ510121A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10558798P 1998-10-26 1998-10-26
PCT/US1999/024054 WO2000024412A2 (en) 1998-10-26 1999-10-26 Use of vegf-c or vegf-d gene or protein to prevent restenosis

Publications (1)

Publication Number Publication Date
NZ510121A true NZ510121A (en) 2003-02-28

Family

ID=22306672

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ510121A NZ510121A (en) 1998-10-26 1999-10-26 Use of VEGF-C or VEGF-D gene or protein to prevent restenosis of blood vessels

Country Status (12)

Country Link
EP (1) EP1126870B1 (https=)
JP (2) JP4769929B2 (https=)
CN (1) CN1338943A (https=)
AT (1) ATE275417T1 (https=)
AU (1) AU768330B2 (https=)
CA (1) CA2340593C (https=)
DE (1) DE69920031T2 (https=)
ES (1) ES2229788T3 (https=)
NO (1) NO20012017L (https=)
NZ (1) NZ510121A (https=)
PT (1) PT1126870E (https=)
WO (1) WO2000024412A2 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6818220B1 (en) 1994-11-14 2004-11-16 Licentia Ltd. Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof
US7423125B2 (en) 1995-08-01 2008-09-09 Vegenics Limited Antibodies to VEGF-C
US6361946B1 (en) 1997-02-05 2002-03-26 Licentia Ltd Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
AU3988401A (en) 2000-02-25 2001-09-03 Ludwig Inst Cancer Res Materials and methods involving hybrid vascular endothelial growth factor dnas and proteins
US7201898B2 (en) * 2000-06-01 2007-04-10 The University Of North Carolina At Chapel Hill Methods and compounds for controlled release of recombinant parvovirus vectors
TWI257307B (en) 2000-07-12 2006-07-01 Orthologic Corp Pharmaceutical composition for cardiac tissue repair
MXPA02003434A (es) 2000-08-04 2002-09-02 Human Genome Sciences Inc Factor de crecimiento endotelial vascular 2.
ATE481097T1 (de) * 2001-01-16 2010-10-15 Vascular Therapies Llc Implantierbare vorrichtung enthaltend resorbierbares matrixmaterial und antiproliferative wirkstoffe zur vorbeugung oder behandlung von versagen vaskulärer hämodialysezugänge und anderer vaskulärer transplantate
CA2444632A1 (en) 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
FI20010898A0 (fi) * 2001-04-30 2001-04-30 Ylae Herttuala Seppo Ekstrasellulaarinen superoksididismutaasi (EC-SOD) geeniterapia restenoosoin ehkäisemiseksi
GB0120690D0 (en) 2001-08-24 2001-10-17 Novartis Ag Organic compounds
AU2003224587A1 (en) * 2002-04-30 2003-11-17 Fit Biotech Oyj Plc Medical device
PL195457B1 (pl) * 2002-08-05 2007-09-28 Zaklady Farm Polpharma Sa Kaseta ekspresyjna, dwucistronowy wektor plazmidowy, środek farmaceutyczny oraz ich zastosowanie
WO2005039556A1 (ja) * 2003-10-29 2005-05-06 Institute Of Medicinal Molecular Design. Inc. 血行再建術後の再狭窄又は再閉塞の治療及び／又は予防のための医薬
WO2005089822A1 (ja) * 2004-03-18 2005-09-29 Kensuke Egashira 薬剤・遺伝子溶出型ステント
EP1919944B1 (en) 2005-08-15 2011-03-23 Vegenics Pty Ltd Modified vegf and pdgf with improved angiogenic properties
CN101563102B (zh) 2006-09-22 2014-12-17 德克萨斯系统大学董事会 治疗内皮功能障碍的方法
KR20100129295A (ko) 2008-02-19 2010-12-08 셀라돈 코포레이션 심근 내 바이러스 벡터의 흡수를 개선시키기 위한 조성물
CN101361988B (zh) * 2008-09-12 2011-12-21 西南交通大学 一种具有生物相容性的血管支架或心脏瓣膜表面涂层的制备方法
WO2012088563A1 (en) * 2010-11-24 2012-07-05 Vegenics Pty Limited Vegfr-2-specific forms of vegf-d and vegf-c and uses thereof
CN108640994A (zh) * 2018-06-28 2018-10-12 浙江众意生物科技有限公司 一种vegf-c单克隆抗体及试剂盒
IL286675B2 (en) * 2019-03-29 2026-02-01 Abiomed Inc Systems and methods for left ventricular unloading in biological therapy or vector gene therapy
CN119454907A (zh) * 2025-01-09 2025-02-18 浙江大学 Vegf-c156s在制备减轻静脉移植物狭窄的药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033917A1 (en) * 1994-11-14 1998-08-06 The Ludwig Institute For Cancer Research Vascular endothelial growth factor c (vegf-c) protein and gene, mutants thereof, and uses thereof
US5830879A (en) * 1995-10-02 1998-11-03 St. Elizabeth's Medical Center Of Boston, Inc. Treatment of vascular injury using vascular endothelial growth factor
WO1998007832A1 (en) * 1996-08-23 1998-02-26 Ludwig Institute For Cancer Research Recombinant vascular endothelial cell growth factor d (vegf-d)
US6013780A (en) * 1996-09-06 2000-01-11 Technion Research & Development Co. Ltd. VEGF145 expression vectors
US5980887A (en) * 1996-11-08 1999-11-09 St. Elizabeth's Medical Center Of Boston Methods for enhancing angiogenesis with endothelial progenitor cells
EP0977854A2 (en) * 1997-04-25 2000-02-09 Collateral Therapeutics Truncated vegf-related proteins

Also Published As

Publication number Publication date
EP1126870A2 (en) 2001-08-29
AU768330B2 (en) 2003-12-11
EP1126870B1 (en) 2004-09-08
NO20012017L (no) 2001-06-26
NO20012017D0 (no) 2001-04-24
JP4769929B2 (ja) 2011-09-07
JP5231587B2 (ja) 2013-07-10
PT1126870E (pt) 2005-01-31
AU1314700A (en) 2000-05-15
CA2340593C (en) 2012-05-08
JP2011173874A (ja) 2011-09-08
ES2229788T3 (es) 2005-04-16
CA2340593A1 (en) 2000-05-04
CN1338943A (zh) 2002-03-06
DE69920031D1 (de) 2004-10-14
WO2000024412A3 (en) 2000-08-03
JP2002528420A (ja) 2002-09-03
ATE275417T1 (de) 2004-09-15
DE69920031T2 (de) 2005-09-22
WO2000024412A2 (en) 2000-05-04

Similar Documents

Publication Publication Date Title
NZ510121A (en) Use of VEGF-C or VEGF-D gene or protein to prevent restenosis of blood vessels
EP1214057A4 (en) COMPOSITION FOR VESSEL COATING
DE69617964D1 (de) Celluloseazetat-zusammensetzungen zur verwendung bei der embolisierung von blutgefässen
EP1283268A3 (en) Recombinant vascular endothelial cell growth factor D (VEGF-D)
DE69620886D1 (de) Zubereitungen zur embolisierung von blutgefässen
IL134042A0 (en) Modified dorsal tissue affecting factor and compositions
WO2001052875A8 (en) Vegf-d/vegf-c/vegf peptidomimetic inhibitor
MXPA01003755A (es) Dominios de ligadura de dedo de zinc para gnn.
IL190542A0 (en) Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei
EP2014678A3 (en) KDR peptides and vaccines comprising the same
ES2218872T3 (es) Polipeptido 10 de tipo citoquina de mamifero.
WO1998033509A3 (en) Useful properties of human lactoferrin and variants thereof
WO1999045098A3 (en) Delivery or proteins into eukaryotic cells with recombinant yersinia
WO1997020933A3 (en) Mutational variants of mammalian ob gene proteins
CA2295040A1 (en) Method for coating stents with dna and expression of recombinant genes from dna coated stent in vivo
ATE291588T1 (de) Endothel-spezifischer expression unter einfluss von epcr kontrollelementen
WO2000074629A3 (fr) Composition destinee a la mise en oeuvre d'un traitement cytotoxique, notamment antitumoral ou antiviral, chez un mammifere
Kodama Small diameter cardiovascular graft
Nocon Selected problems in lighting of bays in the steel industry
高原秀典 Overexpression of protein kinase Cβ isoform by adenoviral gene transfer accelerated intimal hyperplasia in rat carotid artery.
Duan The Effect of Microstructure on the Fatigue Crack Propagation Near the Threshold of Three Titanium Alloys

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)